1. Home
  2. IVVD vs HEQ Comparison

IVVD vs HEQ Comparison

Compare IVVD & HEQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IVVD
  • HEQ
  • Stock Information
  • Founded
  • IVVD 2020
  • HEQ 2011
  • Country
  • IVVD United States
  • HEQ United States
  • Employees
  • IVVD N/A
  • HEQ N/A
  • Industry
  • IVVD Biotechnology: Pharmaceutical Preparations
  • HEQ Investment Managers
  • Sector
  • IVVD Health Care
  • HEQ Finance
  • Exchange
  • IVVD Nasdaq
  • HEQ Nasdaq
  • Market Cap
  • IVVD 66.6M
  • HEQ 126.9M
  • IPO Year
  • IVVD 2021
  • HEQ N/A
  • Fundamental
  • Price
  • IVVD $1.61
  • HEQ $10.65
  • Analyst Decision
  • IVVD Strong Buy
  • HEQ
  • Analyst Count
  • IVVD 4
  • HEQ 0
  • Target Price
  • IVVD $7.89
  • HEQ N/A
  • AVG Volume (30 Days)
  • IVVD 38.4M
  • HEQ 43.1K
  • Earning Date
  • IVVD 03-27-2025
  • HEQ 01-01-0001
  • Dividend Yield
  • IVVD N/A
  • HEQ 9.78%
  • EPS Growth
  • IVVD N/A
  • HEQ N/A
  • EPS
  • IVVD N/A
  • HEQ N/A
  • Revenue
  • IVVD $11,564,000.00
  • HEQ N/A
  • Revenue This Year
  • IVVD N/A
  • HEQ N/A
  • Revenue Next Year
  • IVVD $570.64
  • HEQ N/A
  • P/E Ratio
  • IVVD N/A
  • HEQ N/A
  • Revenue Growth
  • IVVD N/A
  • HEQ N/A
  • 52 Week Low
  • IVVD $0.36
  • HEQ $9.08
  • 52 Week High
  • IVVD $4.74
  • HEQ $11.84
  • Technical
  • Relative Strength Index (RSI)
  • IVVD 63.18
  • HEQ 62.37
  • Support Level
  • IVVD $1.30
  • HEQ $10.43
  • Resistance Level
  • IVVD $2.74
  • HEQ $10.65
  • Average True Range (ATR)
  • IVVD 0.42
  • HEQ 0.11
  • MACD
  • IVVD 0.05
  • HEQ 0.02
  • Stochastic Oscillator
  • IVVD 52.62
  • HEQ 97.50

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest

John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.

Share on Social Networks: